Craig Freeman

Craig Freeman

Toxicologist

UKRT/ERT

Craig joined bibra in 2018 after graduating from the University of Exeter with a BSc in Biological and Medicinal Chemistry. He is regularly involved in projects in the pharmaceutical and medical device sectors, particularly assessments of impurities and of extractables and leachables. He has also produced hazard and risk assessments for clients across a range of other areas, including food, cosmetics and biocides, and prepared REACH registration dossiers in IUCLID for a range of industrial chemicals. Furthermore, Craig contributes summaries to, and is the current editor of, Toxicology and Regulatory News, bibra’s monthly publication on critical developments in toxicology.

Outside of work, Craig likes to keep active and mostly does so by going for bike rides and walks in the countryside. Gardening and watching TV series and sports tend to make up the rest of his spare time.

Craig's case studies and blog posts

In silico prediction of genotoxicity and carcinogenicity

Case study

As part of their overall regulatory requirements, the client was asked to provide an assessment of the known or predicted genotoxicity and carcinogenicity of a number of ingredients in their products. Bibra were provided with a list of several substances and asked to carry out this work following the genetic toxicology in silico (GIST) protocol.

Biocompatibility evaluation of a series of autoinjector medical devices

Case study

The company manufactures a range of parts for use as components in a variety of medical devices.

Toxicological risk assessment of leachables from a combination product

Case study

The client was developing a ready-to-use (RTU) process for the administration of a viral-based product in a clinical setting. Bibra was requested to assist with the assessment of extractables during the development phase and leachables in the final RTU process - viral vector product.

Want to read more case studies and blog posts that Craig has been involved in? Click below to read more.

Contact us